[go: up one dir, main page]

EP1393710A1 - Méthode d'application d'une composition orale - Google Patents

Méthode d'application d'une composition orale Download PDF

Info

Publication number
EP1393710A1
EP1393710A1 EP02255842A EP02255842A EP1393710A1 EP 1393710 A1 EP1393710 A1 EP 1393710A1 EP 02255842 A EP02255842 A EP 02255842A EP 02255842 A EP02255842 A EP 02255842A EP 1393710 A1 EP1393710 A1 EP 1393710A1
Authority
EP
European Patent Office
Prior art keywords
oral
gel
agents
oral care
oral composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02255842A
Other languages
German (de)
English (en)
Inventor
Gaelle Moneuze
Ross Strand
Christopher David White
Michael Kevin Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Priority to EP02255842A priority Critical patent/EP1393710A1/fr
Priority to US10/641,430 priority patent/US20040037789A1/en
Priority to MXPA05001950A priority patent/MXPA05001950A/es
Priority to CA002492790A priority patent/CA2492790A1/fr
Priority to EP03793258A priority patent/EP1542651A1/fr
Priority to JP2004529819A priority patent/JP2005537310A/ja
Priority to AU2003262777A priority patent/AU2003262777A1/en
Priority to PCT/US2003/026269 priority patent/WO2004017933A1/fr
Priority to CNA038189038A priority patent/CN1674860A/zh
Priority to TW092123025A priority patent/TW200407168A/zh
Publication of EP1393710A1 publication Critical patent/EP1393710A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8164—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers, e.g. poly (methyl vinyl ether-co-maleic anhydride)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Definitions

  • the present invention relates to a method of applying oral care benefit agent to the oral tissues. More specifically, the invention relates to a method of application of an oral composition such that the oral composition remains in contact with the oral tissues overnight during rest or slumber.
  • the most frequently used oral care treatments used in the western world are those treatments that are administered by the consumer themselves once or twice a day as part of the daily routine.
  • Examples of such treatments include dentifrices containing for example anti-bacterial plaque actives and/or anti-caries actives and mouth rinses containing anti-bacterial actives and/or breath freshening actives.
  • dentifrices containing for example anti-bacterial plaque actives and/or anti-caries actives and mouth rinses containing anti-bacterial actives and/or breath freshening actives.
  • the applicant is aware that it is a need of the consumer to have 24-hour maintenance of oral health. Whilst some of these treatments claim extended or prolonged therapeutic benefit following the initial treatment, they do not typically meet the needs of the consumer in providing substantial long lasting therapeutic, prophylactic and/or cosmetic treatment benefits. As a result, the only way to achieve sustained active release has been to periodically reapply the product, or to use special delivery mechanisms such as a dental tray. Also, despite the common acceptance and use of extended daily oral regimens
  • US 5,462,728 teaches a water insoluble bioadhesive copolymer matrix containing a therapeutic agent to be applied to the oral cavity.
  • Such water insoluble vehicles are designed to precipitate the polymeric carrier and active agent contained therein upon application to the oral cavity, and are designed for treatment of small areas of the oral cavity.
  • polymeric films require removal by mechanical means such as brushing. This may also result in a palpable hard coating being formed on the oral tissues that is unpleasant to the consumer.
  • US 5,462,728 further discloses a method of applying the oral composition to the oral cavity resulting in the in situ formation of an adhering, water insoluble film that remains active for a period of hours.
  • compositions comprising cellulosic polymers with high levels of ethyl alcohol and carbamide peroxide. Following application, the solvent evaporates, leaving a polymeric film on the teeth delivering the contained carbamide peroxide.
  • the compositions therein are disclosed as being for intermittent or acute application in the treatment of oral conditions. These compositions contain levels of monohydric alcohols above 50% and may cause undesired consumer reactions to palpable layers on the oral tissues. Furthermore, they may require mechanical means of removal following application.
  • US 5,438,076 teaches the use of acrylic polymers to deliver pharmacological agents to the oral cavity. These compositions are designed for application to afflicted areas of the oral cavity, not the oral cavity as a whole, and may result in palpable film formation that some consumers find unpleasant.
  • WO02/34221 Another method of prolonged delivery of oral care benefit agents is described in WO02/34221.
  • This document discloses the application of oral care compositions comprising a silicone resin, a silicone gum and a silicone fluid and an oral care benefit agent.
  • the oral care compositions disclosed by this document form a substantive film on the surface of the teeth or gums and may be "broadly applied to the whole cavity". Due to the composition's substantivity it will remain on the oral tissues for up to 8 hours and requires removal by mechanical means such as brushing or rinsing. Whilst the compositions of WO02/34221 are excellent for providing long-term delivery of oral care benefits, it has been found that some consumers prefer not to have palpable silicone residues on the tissues of the oral cavity the following morning.
  • US 5,631,000 teaches the whitening of teeth with an aqueous gel that is exposed to the oral tissues by being placed in a dental tray that is then worn in the oral cavity.
  • the dental tray is usually worn at night, but may be worn during the day.
  • dental trays are uncomfortable to wear.
  • Application of oral care overnight without the requirement of a dental tray is advantageous due to the ease of application to the oral cavity, and the good aesthetic experience of the consumer.
  • Desirable products require sufficient substantivity and viscosity to enable application to the oral cavity, to adhere to the oral tissues and to release the contained oral care benefit agents over an extended period of time.
  • the viscosity should not be so high that the consumer can feel globular portions of the newly applied product that have not spread well over the oral tissues upon application. It is desirable to have a gel for use in the present invention that enables easy application to the oral cavity, thin layer formation over the oral tissues and even spread into periodontal pockets and fissures
  • a method for treating the oral cavity comprising the application of an aqueous gel to the oral cavity such that at least 75% of the gingival margin or at least 75% of the buccal portion of the hard tissue is coated with the gel, application occurring as part of the daily oral care routine shortly before retiring, and the gel remaining in contact with the oral tissues while sleeping, the gel comprising;
  • the method and aqueous gels provided herein provide means for overnight application and delivery of an aqueous gel comprising oral care benefit agents with improved ease of use and consumer aesthetics.
  • uccal portion means those surfaces of oral tissues closest to the cheeks and inner surfaces of the lips.
  • thickener means any material that when added to a solvent or carrier results in the viscosity of the solvent or carrier increasing.
  • abrasive means any particulate material with polishing or abrasive characteristics that is substantially insoluble in water and has a diameter of from about 1 ⁇ m to about 100 ⁇ m.
  • the invention further relates to aqueous gels for use according to the method above comprising;
  • the invention further relates to a kit for treatment of the oral cavity comprising an oral care gel, an applicator and method of use instructions directed towards the present invention.
  • Viscosity of the gel as used herein unless otherwise stated is measured using a Carri-med CSL 2 rheometer with a gap of 500 ⁇ m and continuous linear ramps of shear rates from 0.1 to 1 s -1 and 1 to 900 s -1 run over 60 s using 0.1 cm 3 of product at 20°C.
  • oral care benefit agent refers to any composition which has a prophylactic, therapeutic or cosmetic benefit either directly within the oral cavity or which is absorbed via the oral cavity but which has its primary benefits elsewhere.
  • oral cavity refers to the cavity from the lips to the epiglottis.
  • the "hard tissues” comprise tissues such as the teeth and periodontal support and the like, and the “soft tissues” comprise tissues such as the gums, the tongue, the surfaces of the buccal cavity and the like.
  • the hard tissues of the oral cavity should also be considered to comprise any devices which are used therein for example dentures, partial dentures, braces and the like.
  • Active and other ingredients useful herein may be categorised or described herein by their cosmetic and/or therapeutic benefit or their postulated mode of action. However, it is to be understood that the active and other ingredients useful herein can, in some instances, provide more than one cosmetic and/or therapeutic benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit an ingredient to the particularly stated application or applications listed.
  • compositions and methods/processes of the present invention can comprise, consist of, and consist essentially of the essential elements and limitations of the invention described herein, as well as any of the additional or optional ingredients, components, steps, or limitations described herein.
  • the present invention is directed to a method of applying an aqueous gel comprising at least one oral care benefit agent to the oral cavity such that at least 75% of the gingival margin is coated with the gel.
  • the gingival margin is of importance, as it is this area where plaque formation can result in gingivitis, and lead to periodontal disease. Coating at least 75% of the gingival margin will result in similar levels of coating on the teeth and gums.
  • Application to a substantial proportion of the gingival margin is advantageous in the treatment of plaque.
  • the gel be applied so that at least at least 75% of the buccal portion of the hard tissue is coated.
  • application is such that 100% of the gingival margin and the hard tissues are coated by the gel.
  • the application is such that the gel is applied to the oral cavity before sleeping and is not intentionally removed from the oral cavity by way of rinsing or mechanical brushing or other such like means before sleeping. It has been found that this method is advantageous in combating the degeneration of the oral cavity overnight and reducing morning mouth malodour.
  • the method comprises the application of the aqueous gel to the oral cavity by the consumer as part of the daily oral hygiene regimen after completing brushing, mouth washing, treatment with dental floss and other such like activities associated with the maintenance of oral hygiene. More preferable is the method wherein the application of the aqueous gel to the oral cavity follows the completion of oral hygiene activities by the consumer, and prior to sleeping.
  • the gel is maintained on, and releases contained oral care benefit agents onto, the tissues of the oral cavity for an extended period of time not less than 15 minutes, preferably not less than 30 minutes and more preferably not less than 1 hour.
  • the aqueous gel to be applied according to the current invention preferably has a combination of good stability characteristics when applied to the oral cavity.
  • the oral care benefit agents of the gel are released onto the oral tissues from the gel after application, and remain adherent to the oral tissues following dissolution of the carrier gel matrix for a period of time not less than 1 hour, preferably 4 hours, more preferably 6 hours and more preferably still 8 hours.
  • This method of sustained delivery is advantageous as sustained delivery of oral care agents to the oral cavity has previously been achieved using insoluble polymers and vehicles that require mechanical removal following treatment, or solid phase support mechanisms that do not have high consumer aesthetics.
  • aqueous gel herein does not form a layer on the oral tissues that is palpable to the consumer upon waking, nor does it require mechanical means of removal.
  • the gel of the present invention comprises at least one oral care benefit agent.
  • Oral care benefit agents of the present invention may be selected from the group including anti-microbial agents, desensitising agents, teeth whitening actives, anti-stain agents, anti-tartar agents, anti-plaque agents, fluoride ion sources, tooth strengthening agents, nutrients, antioxidants, H-2 antagonists and mixtures thereof.
  • the oral care benefit agent may comprise from about 0.01% to about 15% by weight of the gel. The following is a non exclusive list of oral care benefit agents that may be used in the present invention:
  • Teeth whitening actives may be included in the oral care benefit agent of the present invention.
  • the actives suitable for whitening are selected from the group consisting of the peroxides, metal chlorites, perborates, percarbonates, peroxyacids, and combinations thereof.
  • Suitable peroxide compounds include hydrogen peroxide, calcium peroxide, carbamide peroxide, and mixtures thereof.
  • Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite.
  • Additional whitening actives may be the hypochlorite salts and chlorine dioxide.
  • Anti-tartar agents known for use in dental care products include pyrophosphates, linear polyphosphates with 4 or more repeat units, polyphosphonates and mixtures thereof.
  • Pyrophosphate ions delivered to the teeth are derived from pyrophosphate salts.
  • the pyrophosphate salts are described in more detail in Kirk & Othmer, Encyclopedia of Chemical Technology, Third Edition, Volume 17, Wiley-Interscience Publishers (1982).
  • Agents that may be used in place of or in combination with pyrophosphate salts include such known materials as synthetic anionic polymers including polyacrylates and copolymers of maleic anhydride or acid and methyl vinyl ether, as described, for example, in U.S.
  • Patent 4,627,977 to Gaffar et al.; as well as, e.g., polyamino propoane sulfonic acid (AMPS), zinc citrate trihydrate, linear polyphosphates (e.g., tripolyphosphate; hexametaphosphate), diphosphonates (e.g., ethane-1-hydroxy-1,1-diphosphonate, 1-azacycloheptane-1,1-diphosphonate), polypeptides (such as polyaspartic and polyglutamic acids), and mixtures thereof.
  • AMPS polyamino propoane sulfonic acid
  • linear polyphosphates e.g., tripolyphosphate; hexametaphosphate
  • diphosphonates e.g., ethane-1-hydroxy-1,1-diphosphonate, 1-azacycloheptane-1,1-diphosphonate
  • polypeptides such as polyaspartic and polyglutamic acids
  • antitartar agents include polycarboxylates; polyepoxysuccinates; ethylenediaminetetraacetic acid; linear alkyl diphosphonates; linear carboxylic acids; sodium zinc citrate, nitrilotriacetic acid and related compounds.
  • Fluoride ion sources are well known for use in oral care compositions as anticaries agents. Fluoride ions are contained in a number of oral care compositions for this purpose.
  • fluoride ion-yielding materials can be employed as sources of soluble fluoride in the instant aqueous gels. Examples of suitable fluoride ion-yielding materials include sodium fluoride, stannous fluoride and sodium monofluorophosphate.
  • the instant aqueous gels provide from about 50 ppm to 10,000 ppm, more preferably from about 100 to 3000 ppm, of fluoride ions in the aqueous solution.
  • Antimicrobial agents are known to those skilled in the art and include cationic agents, non-cationic agents and metal ion salts. Such agents may include, but are not limited to, 5-chloro-2-(2,4-dichlorophenoxy)-phenol, commonly referred to as triclosan, and described in The Merck Index, 11th ed. (1989), pp. 1529 (entry no. 9573); phthalic acid and its salts, substituted monoperthalic acid and its salts and esters, preferably magnesium monoperoxy phthalate, chlorhexidine ( Merck Index, no. 2090), alexidine ( Merck Index, no. 222; hexetidine ( Merck Index, no.
  • tetradecylpyridinium chloride TPC
  • N-tetradecyl-4-ethylpyridinium chloride TDEPC
  • octenidine delmopinol, octapinol, and other piperidino derivatives
  • iron preparations zinc/stannous ion agents
  • antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, and metronidazole
  • analogs and salts of the above essential oils including thymol, geraniol, carvacrol, citral, hinokitiol, eucalyptol, catechol (particularly 4-allyl catechol) and mixtures thereof; methyl salicylate; hydrogen peroxide; nanochitosan, metal salts of chlorite and mixtures of all of the above.
  • Preferred antimicrobial agents include cetyl pyridinium chloride and triclosan.
  • the antimicrobial agent comprises from about
  • Anti-inflammatory agents can also be present in the aqueous gel of the present invention.
  • Such agents may include, but are not limited to, non-steroidal anti-inflammatory agents (or NSAIDs) such as ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, aspirin, ketoprofen, piroxicam and meclofenamic acid.
  • NSAIDs such as Ketorolac are claimed in U.S. Patent 5,626,838, issued May 6, 1997.
  • Disclosed therein are methods of preventing and, or treating primary and reoccurring squamous cell carcinoma of the oral cavity or oropharynx by topical administration to the oral cavity or oropharynx an effective amount of an NSAID.
  • Nutrients may improve the condition of the oral cavity and can be included in the aqueous gels of the present invention.
  • Nutrients include minerals, vitamins, nutritional supplements, and mixtures thereof.
  • Minerals that can be included with the aqueous gels of the present invention include calcium, phosphorus, fluoride, zinc, manganese, potassium and mixtures thereof. These minerals are disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., ⁇ 1997, pp10-17.
  • Vitamins can be included with minerals or used separately. Vitamins include Vitamins C and D, thiamine, riboflavin, calcium pantothenate, niacin, folic acid, nicotinamide, pyridoxine, cyanocobalamin, para-aminobenzoic acid, bioflavonoids, and mixtures thereof. Such vitamins are disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., ⁇ 1997, pp. 3-10.
  • Nutritional supplements include amino acids, lipotropics, fish oil, protein products, glucose polymers, corn oil, safflower oil, medium chain triglycerides and mixtures thereof, as disclosed in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., ⁇ 1997, pp. 54-54e.
  • Amino acids include, but, are not limited to L-Tryptophan, L-Lysine, Methionine, Threonine, Levocarnitine or L- carnitine and mixtures thereof.
  • Lipotropics include, but are not limited to choline, inositol, betaine, linoleic acid, linolenic acid, and mixtures thereof.
  • Fish oil contains large amounts of Omega-3 (N-3) polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid.
  • Enzymes are biological catalysts of chemical reactions in living systems. Enzymes combine with the substrates on which they act forming an intermediate enzyme-substrate complex. This complex is then converted to a reaction product and a liberated enzyme which continues its specific enzymatic function.
  • Enzymes provide several benefits when used in the oral cavity.
  • Proteases break down salivary proteins which are absorbed onto the tooth surface and form the pellicle; the first layer of plaque.
  • Proteases along with lipases destroy bacteria by lysing proteins and lipids which form the structural component of bacterial cell walls and membranes.
  • Dextranases break down the organic skeletal structure produced by bacteria that forms a matrix for bacterial adhesion.
  • Proteases and amylases not only present plaque formation, but also prevent the development of calculus by breaking-up the carbohydrate-protein complex that binds calcium, preventing mineralization.
  • Enzymes useful in the present invention include any of the commercially available proteases, glucanohydrolases, endoglycosidases, amylases, mutanases, lipases and mucinases or compatible mixtures thereof.
  • Preferred are the proteases, dextranases, endoglycosidases and mutanases, most preferred being papain, endoglycosidase or a mixture of dextranase and mutanase.
  • Antioxidants are generally recognized as useful in aqueous gels such as those of the present invention. Antioxidants are disclosed in texts such as Cadenas and Packer, The Handbook of Antioxidants , ⁇ 1996 by Marcel Dekker, Inc. Antioxidants that may be included in the aqueous gel or substance of the present invention include, but are not limited to Vitamin E, ascorbic acid, Uric acid, carotenoids, Vitamin A, flavonoids and polyphenols, herbal antioxidants, melatonin, aminoindoles, lipoic acids and mixtures thereof.
  • H-2 antagonists are compounds that block H-2 receptors, but do not have meaningful activity in blocking histamine-1 (H-1 or H?) receptors.
  • H-2 antagonists stimulate the contraction of smooth muscle from various organs, such as the gut and bronchi; this effect can be suppressed by low concentrations of mepyramine- a typical antihistaminic drug.
  • the pharmacological receptors involved in these mepyramine-sensitive histamine responses have been defined as H-1 receptors (Ash, A.S.F. & H.O. Schild, Brit. J. Pharmacol Chemother., Vol. 27 (1966), p. 427).
  • the H-2 antagonists useful in the aqueous gels are those that block the receptors involved in mepyramine-insensitive, non-H-1 (H-2), histamine responses, and do not block the receptors involved in mepyramine-sensitive histamine responses.
  • H-2 antagonists meeting the above criteria include cimetidine, etintidine, ranitidine, ICIA-5165, tiotidine, ORF-17578, lupitidine, donetidine, famotidine, roxatidine, pifatidine, lamtidine, BL-6548, BMY-25271, zaltidine, nizatidine, mifentidine, BMY-52368, SKF-94482, BL-6341A, ICI-162846, ramixotidine, Wy-45727, SR-58042, BMY-25405, loxtidine, DA-4634, bisfentidine, sufotidine, ebrotidine, HE-30-256, D-16637, FRG-8813, FRG-8701, impromidine, L-643728, and HB-408. 4, as disclosed in US 5,294,433 and 5,364,616.
  • the method of the present invention comprises application of a gel.
  • the gel is a high viscosity matrix formed from thickeners known in the art which are safe for oral use and do not react with or inactivate the oral care benefit agents incorporated into them. Furthermore, the gel formed with these thickeners may provide sufficient adhesive attachment to the teeth or mucosa to keep them coated for a period of not less than 15 minutes.
  • the amount of thickener required to form the gel is such that the viscosity of the gel is greater than about 10 Pa.s at a shear rate of 0.1 s -1 .
  • the amount of thickener is such that the viscosity is from about 0.1 Pa.s to about 300 Pa.s, preferably from about 30 Pa.s to about 200 Pa.s, and more preferably from about 80 Pa.s to about 120 Pa.s at a shear rate of 1 s -1 .
  • Suitable thickening agents useful in the present invention include polysaccharide thickeners, clays, cross-linked poly-acrylates, co-polymers, polyethylene glycols and derivatives, protein thickeners and mixtures thereof.
  • Preferred levels of thickener to form the gel are from about 0.1% to about 15%, preferably from about 0.5% to about 10%, more preferably from about 2% to about 5%, by weight.
  • Polysaccharide thickeners useful in the present invention include hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), carboxymethylcellulose (CMC, cellulose gum), methylcellulose, cetylhydroxyethylcellulose, methylhydroxyethylcellulose, microcrystalline cellulose, hydroxyethylethylcellulose, methylhydroxypropylcellulose, carboxymethylhydroxyethylcellulose, xanthan gum, sclerotium gum, carboxymethyl hydroxypropyl guar, guar gum, glyceryl alginate, guar (cyanopsis tetragonoloba) gum, guar hydroxypropyltrimonium chloride, gum arabic/gum acacia, hydroxypropyl guar, karaya (sterculia urens) gum, gellan gum, agar, carrageenan (kappa, iota, lambda), pectin,
  • Clays useful in the present invention include sodium magnesium silicate, lithium magnesium silicate, lithium magnesium sodium silicate, sodium magnesium fluorolithosilicate, bentonite, montmorillonite clay and mixtures thereof.
  • Cross-linked polyacrylates useful in the present invention include sodium acrylate/vinyl alcohol copolymer, acrylate/c10-30 alkyl acrylate crosspolymer, acrylates/ceteth-20 itaconate copolymer, acrylates/ceteth-20 methacrylate copolymer, acrylates/steareth-50 acrylate copolymer, acrylates/steareth-20 itaconate copolymer, acrylates/steareth-20 methacrylate copolymer, carbomer, glycerin/glyceryl polyacrylate and mixtures thereof.
  • Synthetic copolymers useful in the present invention include Poloxamer 407, PVM/MA co-polymer, (commercially available under the trade name “Gantrez”), PVP (poly(vinylpyrrolidone)), polyacrylamideomethylpropane sulfonic acid and mixtures thereof.
  • Polyethylene glycols useful in the present invention include PEG -2M, PEG-5M, PEG-7M, PEG-9M, PEG-14M, PEG-20M, PEG-23M, PEG-25M, PEG-45M, PEG-90M, PEG-115M, PEG-160M, PEG-crosspolymer, PEG-140 glyceryl tristearate and mixtures thereof.
  • Preferred thickeners for use in the present invention are the polysaccharide thickeners and the co-polymers. More preferred are the water-soluble cellulosic and acrylic thickeners. Most preferred is HPMC.
  • HPMC Most preferred is HPMC.
  • the aqueous gel may comprise from about 2.1% to 4.9% HPMC, preferably from 2.5% to 4.7% and more preferably from 2.8% to 4.3% by weight. It has been found that some oral care benefit agents react with thickeners to modify the visocisty of the gel synergistically. More specifically, it has been found that combinations of quaternary anti-microbials with cellulosic thickeners thickens the gel more effectively than when cellulosic thickeners are used on their own.
  • CPC cetylpyridinium chloride
  • the water present in the gel should preferably be deionized and free of organic impurities.
  • Water typically comprises from about 0.1% to 95%, preferably from about 5% to about 90%, and most preferably from about 10% to about 80%, by weight of the gel. This amount of water includes the free water that is added plus that amount that is introduced with other materials.
  • the aqueous gel for use in the present invention may optionally comprise xylitol.
  • Xylitol is a polyol that may be added to provide sweetening and flavouring.
  • xylitol may have some positive benefits as an anti-caries agent.
  • the aqueous gel may comprise from about 0.1% to about 15% xylitol, preferably from about 1% to 10%, and more preferably from about 2% to 8% xylitol.
  • a pH adjusting agent may also be added to optimize the storage stability of the gel and to make the substance safe for oral tissue.
  • These pH adjusting agents, or buffers can be any material which is suitable to adjust the pH of the aqueous gel. Suitable materials include sodium bicarbonate, sodium phosphate, sodium hydroxide, ammonium hydroxide, sodium stannate, triethanolamine, citric acid, hydrochloric acid, sodium citrate, and combinations thereof.
  • the pH adjusting agents are generally added in sufficient amounts so as to adjust the pH of the gel to about 4.5 to about 11, preferably from about 5 to about 9, and more preferably from about 5 to about 8. pH adjusting agents are generally present in an amount of from about 0.01% to about 15% and preferably from about 0.05% to about 5%, by weight.
  • Carrier materials can be humectants. Suitable humectants include glycerin, sorbitol, polyethylene glycol, propylene glycol, and other edible polyhydric alcohols. Humectants are generally present in an amount of from about 10% to about 50% and preferably from about 15% to about 40%, by weight of the aqueous gel.
  • the gel of the present invention may comprise a number of other components. Additional components include, but are not limited to, flavoring agents, sweetening agents, opacifiers, coloring agents, emulsifiers and chelants such as ethylenediaminetetraacetic acid. These additional ingredients can also be used in place of the compounds disclosed above.
  • Flavours, sweetners, colours and sensates may comprise from about 0.1% to about 10% by weight of the gel for use in the current invention.
  • the aqueous gel of the present invention preferably comprises not more than about 18% C 1 -C 6 monohydric alcohols. Higher alcohol levels in a gel intended for overnight use are potentially deleterious. However, it is known to those skilled in the art that polyhydric alcohols disclosed above are useful as humectants in gels. Preferably, the aqueous gel contains less than 10% monohydric alcohols, more preferably less than 5%, and more preferably still contains no monohydric alcohols. These levels are desirable to maintain safety and gel aesthetics.
  • the aqueous gel preferably comprises less than 5% abrasives.
  • Abrasives whilst useful in dentifrices, are not desirable in the current invention.
  • the gel comprises less than 4% abrasives, more preferably less than 2% abrasives and more preferably still comprises no abrasives. The applicant has found that low levels of abrasives are desirable to maintain consumer compliance and good gel aesthetics.
  • the aqueous gel of the present invention may comprise moderate levels of silicones. Silicones may be desirable to aid the modification of the rheology and substantivity. However, high levels of silicones are undesirable as some consumers would prefer the gel not to be as substantive as gels containing higher levels of silicones. Gels with moderate levels of silicones are desirable as they provide improved mouth feel and sensate delivery.
  • Aqeous gels for use in the present invention comprise less than 10%, preferably from about 0.05% to about 9%, more preferably from about 0.1% to about 8%, by weight, of a silicone. Suitable silicones for use in the present invention include those disclosed in WO 01/01940.
  • Preferred silicones include silicone resins, silicone gums and silicone fluids having a viscosity, at 25°C, of from about 1x10 -6 m 2 /s to about 1x10 -3 m 2 /s. More preferred are the silicone fluids. More preferred still are the polysiloxane fluids include linear polysiloxane polymers such as the linear dimethicones having a molecular weight of at least 4000 and where R is a methyl substituent, and other low viscosity analogues of the polysiloxane materials. Also preferred are the alkyl and alkoxy substituted dimethicone polyols as disclosed in WO 96/33693.
  • the present invention may comprise a kit for the application of overnight oral gel, comprising an oral care gel, an applicator and method of use instructions directed towards application and overnight use of the gel therein.
  • the aspects and embodiments of the present invention set forth in this document have many advantages. For example, they can provide increased efficacy of delivery of oral care benefit agents that provide for better oral hygiene. Similarly, overnight treatment of the oral cavity may result in a reduction of "morning mouth" experienced by the consumer. Furthermore, overnight application of oral care benefit agents may result in effective reduction in the degeneration of the oral cavity accelerated by the conditions imparted by sleeping. Various embodiments of the present invention address the need for better consumer aesthetics and appeal of intensive oral treatments combined with increased ease of application.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
EP02255842A 2002-08-21 2002-08-21 Méthode d'application d'une composition orale Withdrawn EP1393710A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP02255842A EP1393710A1 (fr) 2002-08-21 2002-08-21 Méthode d'application d'une composition orale
US10/641,430 US20040037789A1 (en) 2002-08-21 2003-08-15 Method of applying oral composition
MXPA05001950A MXPA05001950A (es) 2002-08-21 2003-08-20 Un metodo para aplicar una composicion oral para uso en este metodo.
CA002492790A CA2492790A1 (fr) 2002-08-21 2003-08-20 Technique d'application de composition buccale et composition buccale a cet effet
EP03793258A EP1542651A1 (fr) 2002-08-21 2003-08-20 Technique d'application de composition buccale et composition buccale a cet effet
JP2004529819A JP2005537310A (ja) 2002-08-21 2003-08-20 口腔用組成物の適用方法で使用するための口腔用組成物を適用する方法
AU2003262777A AU2003262777A1 (en) 2002-08-21 2003-08-20 A method of applying an oral composition and oral composition for use in this method
PCT/US2003/026269 WO2004017933A1 (fr) 2002-08-21 2003-08-20 Technique d'application de composition buccale et composition buccale a cet effet
CNA038189038A CN1674860A (zh) 2002-08-21 2003-08-20 施用用于此方法的口腔组合物的方法
TW092123025A TW200407168A (en) 2002-08-21 2003-08-21 Oral composition for treating the oral cavity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02255842A EP1393710A1 (fr) 2002-08-21 2002-08-21 Méthode d'application d'une composition orale

Publications (1)

Publication Number Publication Date
EP1393710A1 true EP1393710A1 (fr) 2004-03-03

Family

ID=31197957

Family Applications (2)

Application Number Title Priority Date Filing Date
EP02255842A Withdrawn EP1393710A1 (fr) 2002-08-21 2002-08-21 Méthode d'application d'une composition orale
EP03793258A Withdrawn EP1542651A1 (fr) 2002-08-21 2003-08-20 Technique d'application de composition buccale et composition buccale a cet effet

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP03793258A Withdrawn EP1542651A1 (fr) 2002-08-21 2003-08-20 Technique d'application de composition buccale et composition buccale a cet effet

Country Status (9)

Country Link
US (1) US20040037789A1 (fr)
EP (2) EP1393710A1 (fr)
JP (1) JP2005537310A (fr)
CN (1) CN1674860A (fr)
AU (1) AU2003262777A1 (fr)
CA (1) CA2492790A1 (fr)
MX (1) MXPA05001950A (fr)
TW (1) TW200407168A (fr)
WO (1) WO2004017933A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021170065A1 (fr) * 2020-02-26 2021-09-02 The Procter & Gamble Company Compositions de soins buccodentaires pour favoriser la santé des gencives
WO2021170064A1 (fr) * 2020-02-26 2021-09-02 The Procter & Gamble Company Compositions de soin buccal pour la santé de la gencive

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818150B2 (en) * 2000-12-22 2004-11-16 Chevron Phillips Chemical Company Lp UV- or heat-triggered low oxygen packaging system employing an oxidizable polymer resin and a peroxide
US20050281758A1 (en) * 2004-06-18 2005-12-22 Dodd Kenneth T Oral care compositions
EP1669056A3 (fr) * 2004-08-12 2007-05-30 The Procter and Gamble Company Composition et système de soins buccaux
US20060034784A1 (en) * 2004-08-12 2006-02-16 The Procter & Gamble Company Oral compositions and systems
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
US20080045575A1 (en) * 2004-12-29 2008-02-21 Van Dyke Thomas E Delivery of H2 Antagonists
US7504045B2 (en) * 2005-06-07 2009-03-17 Cryovac, Inc. Method of triggering a film containing an oxygen scavenger
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US20100215744A1 (en) * 2008-08-06 2010-08-26 Medicis Pharmaceutical Corporation Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical
US20070098785A1 (en) * 2005-11-02 2007-05-03 Tim Clarot Medicant delivery system and device
WO2007066837A1 (fr) * 2005-12-06 2007-06-14 Lg Household & Health Care Ltd. Systemes de distribution d'un composant de blanchiment des dents faisant appel a la gelification in situ
US20070238808A1 (en) * 2006-03-09 2007-10-11 Goldberg A J Dental materials, methods of making and using the same, and articles formed therefrom
WO2007134337A2 (fr) * 2006-05-15 2007-11-22 Zicare, Llc Méthode de prévention et de réduction de l'accumulation de tartre
US20070292370A1 (en) * 2006-05-15 2007-12-20 Tim Clarot Method for improving oral health
WO2007134331A2 (fr) * 2006-05-15 2007-11-22 Zicare, Llc Système, kit et procédé pour favoriser et maintenir la santé bucco-dentaire
US8871183B2 (en) * 2006-05-15 2014-10-28 Zicare, Llc Composition for promoting and maintaining oral health
US20070292531A1 (en) * 2006-05-15 2007-12-20 Tim Clarot Composition for oral use and methods for application of same
ES2539114T3 (es) 2006-07-20 2015-06-26 Izun Pharmaceuticals Corporation Enjuague formador de película
CA2661162C (fr) * 2006-08-21 2012-07-03 Creative Specialty Products, Llc Bande pour blanchir les dents
US20090087461A1 (en) * 2007-10-01 2009-04-02 Thomas James Boyd Anti-bacterial pyrocatechols and related methods
JP5317512B2 (ja) * 2008-03-31 2013-10-16 小林製薬株式会社 含嗽用組成物
JP5461785B2 (ja) * 2008-03-31 2014-04-02 小林製薬株式会社 繰り返し感染予防用の医薬組成物
WO2010017310A1 (fr) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Procédé pour le traitement de l'acné, et certaines formes posologiques de celui-ci
RU2011150521A (ru) * 2009-05-13 2013-06-20 ПРОТЕИН ДЕЛИВЕРИ СОЛЮШНЗ, ЭлЭлСи Фармацевтическая система для трансмембранной доставки
US8778387B2 (en) 2009-09-02 2014-07-15 Hyprotek, Inc. Antimicrobial medical dressings and protecting wounds and catheter sites
MX2012008482A (es) * 2010-01-22 2012-11-29 Hyprotek Inc Agentes antimicrobianos que comprenden peroxido, alcohol y agente quelatador.
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US10617472B2 (en) 2012-02-06 2020-04-14 Hyprotek, Inc. Adhesive patch with antimicrobial composition
ITMI20120883A1 (it) 2012-05-22 2013-11-23 Brux S R L Nuova formulazione per la prevenzione della carie dentale
EP2737902A1 (fr) * 2012-11-28 2014-06-04 Zarzatech, Inc. Compositions comprenant de la cimétidine et n, o-carboxyméthyl-chitosane pour la prévention et la thérapie de pathologies de la peau et des membranes muqueuses et dans le domaine de l'odontostomatologie
WO2018058498A1 (fr) * 2016-09-30 2018-04-05 The Procter & Gamble Company Compositions de soins buccaux pour favoriser la santé des gencives
JP2022538521A (ja) 2019-06-14 2022-09-05 ザ プロクター アンド ギャンブル カンパニー 洗い流さない口腔ケア組成物
MX2021015126A (es) 2019-06-14 2022-01-24 Procter & Gamble Composiciones para el cuidado bucal para usar y no enjuagar.
WO2021047997A1 (fr) 2019-09-10 2021-03-18 Unilever Ip Holdings B.V. Émulsions eau dans huile pour soins bucco-dentaires
CN112426242B (zh) * 2020-12-09 2022-08-16 海南光宇生物科技有限公司 一种生物纤维素洁齿牙套

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015592A1 (fr) * 1989-06-12 1990-12-27 Patrick John Shanahan Dentifrice anti-plaque
JPH07126133A (ja) * 1993-11-05 1995-05-16 Lion Corp 口腔用ゲル組成物
EP0743059A2 (fr) * 1995-05-18 1996-11-20 Colgate-Palmolive Company Procédé d'application d'une composition orale antibactérienne sur les surfaces d'implants dentaires
EP0864315A2 (fr) * 1997-03-11 1998-09-16 Sunstar Inc. Composition à usage oral
WO1999020237A1 (fr) * 1997-10-17 1999-04-29 Zakrytoe Aktsionernoe Obschestvo Ostim Composition buccale

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5176901A (en) * 1991-04-10 1993-01-05 Smithkline Beecham Corporation Dental composition
US5462728A (en) * 1994-04-05 1995-10-31 Blank; Izhak Pharmaceutical compositions
US5695746A (en) * 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
US6096328A (en) * 1997-06-06 2000-08-01 The Procter & Gamble Company Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6569408B1 (en) * 1999-07-02 2003-05-27 The Procter & Gamble Company Compositions comprising organosiloxane resins for delivering oral care substances
US6649147B1 (en) * 1999-07-02 2003-11-18 The Procter & Gamble Company Delivery system for oral care compositions comprising organosiloxane resins using a removable backing strip
US6589512B1 (en) * 1999-07-02 2003-07-08 The Procter & Gamble Company Compositions comprising organosiloxane resins for delivering oral care substances

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015592A1 (fr) * 1989-06-12 1990-12-27 Patrick John Shanahan Dentifrice anti-plaque
JPH07126133A (ja) * 1993-11-05 1995-05-16 Lion Corp 口腔用ゲル組成物
EP0743059A2 (fr) * 1995-05-18 1996-11-20 Colgate-Palmolive Company Procédé d'application d'une composition orale antibactérienne sur les surfaces d'implants dentaires
EP0864315A2 (fr) * 1997-03-11 1998-09-16 Sunstar Inc. Composition à usage oral
WO1999020237A1 (fr) * 1997-10-17 1999-04-29 Zakrytoe Aktsionernoe Obschestvo Ostim Composition buccale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 08 29 September 1995 (1995-09-29) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021170065A1 (fr) * 2020-02-26 2021-09-02 The Procter & Gamble Company Compositions de soins buccodentaires pour favoriser la santé des gencives
WO2021170064A1 (fr) * 2020-02-26 2021-09-02 The Procter & Gamble Company Compositions de soin buccal pour la santé de la gencive
AU2021225919B2 (en) * 2020-02-26 2024-08-08 The Procter & Gamble Company Oral care compositions for gum health
AU2024205744B2 (en) * 2020-02-26 2025-09-04 The Procter & Gamble Company Oral care compositions for gum health

Also Published As

Publication number Publication date
TW200407168A (en) 2004-05-16
WO2004017933A1 (fr) 2004-03-04
CA2492790A1 (fr) 2004-03-04
AU2003262777A1 (en) 2004-03-11
US20040037789A1 (en) 2004-02-26
JP2005537310A (ja) 2005-12-08
EP1542651A1 (fr) 2005-06-22
CN1674860A (zh) 2005-09-28
MXPA05001950A (es) 2005-04-28

Similar Documents

Publication Publication Date Title
US20040037789A1 (en) Method of applying oral composition
US6096328A (en) Delivery system for an oral care substance using a strip of material having low flexural stiffness
AU2002242342B2 (en) Oral care kits and compositions
AU2002247356B2 (en) Systems for delivering a cosmetic and/or therapeutic active to oral surfaces
US20070254067A1 (en) Consumer customizable oral care products
EP1779846A2 (fr) Système de délivrance d'une substance d'application orale utilisant une bande de matériau comportant une faible rigidité à la flexion
CA2633693A1 (fr) Compositions comprenant des adhesifs a la silicone sensibles a la pression destinees a l'administration de substances pour soins buccaux
US20060034784A1 (en) Oral compositions and systems
JP2009221208A (ja) 口腔用組成物及びそのシステム
US20070259011A1 (en) Oral care products

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20040715

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

17Q First examination report despatched

Effective date: 20070116

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070530